Streetbeat News

Regulatory

BMY

The FDA has accepted Bristol Myers Squibb's application for a subcutaneous form of Nivolumab, combined with Hyaluronidase, setting a Prescription Drug User Fee Act goal date of February 28, 2025.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 11:01 am

CVX

Chevron Pipe Line Company, a Chevron Corp subsidiary, and American Aerospace Technologies have received a unique FAA waiver to fly unmanned aircraft for surveillance in the San Joaquin Valley. This AiRanger UAS will enhance monitoring of Chevron's pipeline and production facilities.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:15 am

MNKD

MannKind Corporation announced that the FDA has granted Fast Track Designation for its Clofazimine Inhalation Suspension (MNKD-101) aimed at treating Nontuberculous Mycobacterial Lung Disease. This designation is expected to expedite the development and review process for MNKD-101, potentially bringing this new treatment option to patients sooner.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:10 am

AMKBY

A. P. Moller Maersk (OTC:AMKBY), the world's largest container shipping company, announced that disruptions in the Red Sea, caused by attacks from Iran-aligned Houthi militants, are expected to reduce the shipping industry's capacity between the Far East and Europe by 15%-20% in Q2. These disruptions have forced vessels to reroute, leading to longer journey times and increased freight rates. Maersk has leased over 125,000 additional containers to enhance reliability and address the capacity shortage, with disruptions likely to persist until the end of the year.

Portfolio Pulse from Benzinga Neuro

May 06, 2024 | 9:18 am

URGN

UroGen Pharma Ltd. announced results from the ATLAS trial, showing that UGN-102 demonstrates sustained response rates in both new and recurrent bladder cancer patients at 12 months. The study focused on low-grade intermediate-risk non-muscle invasive bladder cancer patients treated with UGN-102, with or without subsequent TURBT.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:42 am

GEHC

GE HealthCare has introduced the SIGNA MAGNUS, a head-only magnetic resonance scanner aimed at advancing neuroscience research. The device, which is pending FDA 510(k) approval, represents a significant improvement over traditional whole-body MR systems, particularly in the fields of neurology, oncology, and psychiatry.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:25 am

LTRN

Lantern Pharma Inc. (LTRN) has announced a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of the drug candidate XCE853, a protein disulfide isomerase inhibitor aimed at treating various cancer indications. This collaboration will utilize Lantern's RADR AI platform to identify biomarkers and efficacy-associated signatures for XCE853, potentially guiding future clinical development and patient selection.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:00 am

BYDDY

NIO

XPEV

Chinese EV makers, including SAIC, Chery, Great Wall Motor, and BYD Co., have seen a 40% increase in overseas sales in Q1 2024, reaching 470,000 units. Europe and Asia are the main markets for these exports. BYD Co. leads in NEV overseas sales, followed by SAIC, Geely, Xpeng, and Nio. BYD is adopting a premium pricing strategy in Europe, and Chinese EV makers are exploiting a loophole for exporting 'used' cars to bypass trade barriers.

Portfolio Pulse from Benzinga Neuro

May 06, 2024 | 6:07 am

GOOGL

TSLA

Texas Governor Greg Abbott's anti-immigration measures along the Texas-Mexico border have led to significant environmental degradation, particularly in Eagle Pass. The construction of a new $170 million facility, Camp Eagle, for Texas National Guards, as part of Operation Lone Star, has exacerbated the situation, costing over $11 billion. The environmental damage has sparked concerns among residents and environmentalists. Meanwhile, tech leaders like Sundar Pichai of Alphabet Inc. and Elon Musk of Tesla Inc. have called for updated U.S. immigration policies to attract AI and tech talent, highlighting the broader implications of immigration policies.

Portfolio Pulse from Benzinga Neuro

May 06, 2024 | 6:03 am

NVO

Elon Musk endorsed Novo Nordisk's Ozempic, a drug primarily for Type 2 diabetes, as a solution to childhood obesity, sparking a conversation on the topic. Musk's support for Ozempic, highlighted in a response to a post about obesity policies on X, brings attention to the obesity issue in the U.S. and Japan. Novo Nordisk, the maker of Ozempic, has also launched Wegovy in Japan to address obesity, amidst concerns over the high cost of these drugs.

Portfolio Pulse from Ananya Gairola

May 06, 2024 | 3:50 am